2
IRUS TotalDownloads
SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement
File | Description | Size | Format | |
---|---|---|---|---|
![]() | Accepted version | 155.07 kB | Microsoft Word | View/Open |
![]() | Accepted version | 32.96 kB | Microsoft Word | View/Open |
![]() | Accepted version | 13.97 kB | Microsoft Word | View/Open |
![]() | Accepted version | 12.41 kB | Microsoft Word | View/Open |
![]() | Accepted version | 122.82 kB | Adobe PDF | View/Open |
![]() | Accepted version | 78.16 kB | Adobe PDF | View/Open |
Title: | SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement |
Authors: | Alexander, J Hart, A Segal, JP Powell, N |
Item Type: | Journal Article |
Abstract: | SARS-CoV-2 has caused a global health crisis and mass vaccination programmes provide the best opportunity for controlling transmission and protecting populations. Despite the impressive clinical trial results of the BNT162b2 (Pfizer/BioNTech), ChAdOx1 nCoV-19 (Oxford/AstraZeneca), and mRNA-1273 (Moderna) vaccines, important unanswered questions remain, especially in patients with pre-existing conditions. In this position statement endorsed by the British Society of Gastroenterology Inflammatory Bowel Disease (IBD) section and IBD Clinical Research Group, we consider SARS-CoV-2 vaccination strategy in patients with IBD. The risks of SARS-CoV-2 vaccination are anticipated to be very low, and we strongly support SARS-CoV-2 vaccination in patients with IBD. Based on data from previous studies with other vaccines, there are conceptual concerns that protective immune responses to SARS-CoV-2 vaccination may be diminished in some patients with IBD, such as those taking anti-TNF drugs. However, the benefits of vaccination, even in patients treated with anti-TNF drugs, are likely to outweigh these theoretical concerns. Key areas for further research are discussed, including vaccine hesitancy and its effect in the IBD community, the effect of immunosuppression on vaccine efficacy, and the search for predictive biomarkers of vaccine success. |
Issue Date: | 1-Mar-2021 |
Date of Acceptance: | 13-Jan-2021 |
URI: | http://hdl.handle.net/10044/1/85567 |
ISSN: | 2468-1253 |
Publisher: | Elsevier |
Start Page: | 218 |
End Page: | 224 |
Journal / Book Title: | The Lancet Gastroenterology and Hepatology |
Volume: | 6 |
Issue: | 3 |
Copyright Statement: | © 2021 Elsevier Ltd. All rights reserved. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence http://creativecommons.org/licenses/by-nc-nd/4.0/ |
Sponsor/Funder: | Crohn's & Colitis UK Imperial College Healthcare NHS Trust- BRC Funding |
Funder's Grant Number: | M2019/2 Powell RDA27 |
Keywords: | Science & Technology Life Sciences & Biomedicine Gastroenterology & Hepatology INFLUENZA VACCINE IMMUNE-RESPONSES CROHNS-DISEASE IMMUNOSUPPRESSION CHILDREN THERAPY 2019-nCoV Vaccine mRNA-1273 BNT162 Vaccine COVID-19 COVID-19 Vaccines ChAdOx1 nCoV-19 Disease Transmission, Infectious Gastroenterology Humans Immunocompromised Host Inflammatory Bowel Diseases SARS-CoV-2 Societies, Medical United Kingdom Vaccination Inflammatory Bowel Disease section of the British Society of Gastroenterology and the the Inflammatory Bowel Disease Clinical Research Group Humans Inflammatory Bowel Diseases Vaccination Gastroenterology Immunocompromised Host Societies, Medical Disease Transmission, Infectious United Kingdom COVID-19 SARS-CoV-2 COVID-19 Vaccines BNT162 Vaccine 2019-nCoV Vaccine mRNA-1273 ChAdOx1 nCoV-19 |
Publication Status: | Published |
Online Publication Date: | 2021-01-26 |
Appears in Collections: | Department of Metabolism, Digestion and Reproduction Faculty of Medicine Imperial College London COVID-19 |
This item is licensed under a Creative Commons License